

6. Chang YH, Chuang CK, Pang ST, et al. Prognostic value of TNM stage and tumor necrosis for renal cell carcinoma. *Kaohsiung Journal of Medical Sciences*. 2011; 27(2): 59–63.
7. An JS, Packiam VT, Chennamadhavuni A, et al. Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma. *Frontiers in Oncology*. 2022; 11.
8. Wagener N, Edelmann D, Benner A, et al. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. *Plos One*. 2017; 12(9).
9. Warren AY, Harrison D. WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. *World Journal of Urology*. 2018; 36(12): 191326.
10. Lin TF, Lin WR, Chen M, et al. Compare fuhrman nuclear and chromophobe tumor grade on chromophobe RCC. *Open Medicine*. 2019; 14(1): 336–42.
11. Ohashi R, Martignoni G, Hartmann A, et al. Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. *Virchows Archiv*. 2020; 476(3): 409–18.
12. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma - A study of 101 cases. *American Journal of Surgical Pathology*. 2001; 25(3): 275–84.
13. Lee SE, Byun SS, Oh JK, et al. Significance of macroscopic tumor necrosis as a prognostic indicator for renal cell carcinoma. *Journal of Urology*. 2006; 176(4): 1332–7.
14. Vasudev NS, Wilson M, Stewart GD, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. *Bmj Open*. 2020; 10(5).
15. O'Brian D, Prunty M, Hill A, Shoag J. The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers. *Frontiers in Immunology*. 2021; 12.
16. Teishima J, Kobatake K, Shinmei S, et al. The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. *Urologic Oncology-Seminars and Original Investigations*. 2017; 35(11).
17. Jabs WJ, Busse M, Kruger S, et al. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. *Kidney International*. 2005; 68(5): 2103–10.
18. Tamura K, Matsushita Y, Watanabe H, et al. Feasibility of the ACL (albumin, C-reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first-line targeted therapy. *Urologic Oncology-Seminars and Original Investigations*. 2020; 38(1).
19. Tamura K, Ando R, Takahara K, et al. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy. *Urologic Oncology-Seminars and Original Investigations*. 2021; 39(1).
20. Yilmaz H, Yilmaz A, Demirag G. Prognostic significance of hemoglobin-to-red cell distribution width ratio in patients with metastatic renal cancer. *Future Oncology*. 2021; 17(29): 3853–64.
21. Basmaci I, Celik S, Sefik E, et al. Evaluation of the Prognostic Value of Preoperative Neutrophil-to-lymphocyte Ratio in Renal Cell Carcinoma. *Journal of Urological Surgery*. 2019; 6(3): 218–24.
22. Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. *Cancer*. 2006; 107(8): 1793–800.
23. Zhang ND, Zhang HN, Zhu DQ, et al. Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. *International Journal of Surgery*. 2020; 79: 66–73.
24. Shen J, Chen Z, Zhuang QF, et al. Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. *Plos One*. 2016; 11(11).